Helius Medical Technologies and Sol Strategies may look like unrelated businesses at first glance, yet both have shifted toward the same core idea: serving as publicly traded ways to gain exposure to the Solana blockchain. This alignment makes a direct comparison straightforward, because both rely on staking revenue and validator infrastructure linked to SOL. For investors considering Solana-related equities, it helps to examine how the two differ in treasury size, business approach, leverage levels, and overall positioning when assessing their performance and risk profiles.
HSDT (Helius Medical Technologies, Inc.) has completed a major transition, moving away from its original medical-device operations to focus on Solana digital-asset treasury and infrastructure activities. The company sold off its legacy medical holdings and redirected resources into building a SOL position that now stands at roughly 2.4 million tokens. Third-quarter results highlighted the change, with revenue rising sharply year over year to around $3.4 million, almost all from staking activities. Its net staking yield reached about 5.9% APY, which exceeded the broader Solana network average. The Pacific Backbone validator setup is now live, attracting roughly 1 million SOL in third-party delegations, and the firm was chosen by the Hong Kong SAR government as a strategic enterprise. Net income figures have been shaped largely by unrealized gains on digital assets, reflecting the stock's close tie to SOL price movements alongside a relatively modest cash position. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
STKE (Sol Strategies Inc.) is a Canadian-listed company that rebranded from its earlier Cypherpunk Holdings identity to become one of the first Solana-focused treasury firms on Nasdaq. It maintains a smaller SOL holding of about 533,000 tokens and runs validator nodes on proof-of-stake networks, mainly Solana and SUI. Recent steps include acquiring Houdini Swap, a cross-chain swap aggregator, and adding Darklake Labs' zero-knowledge privacy technology to build transactional revenue alongside staking. The company also introduced the StakeSol liquid staking token earlier this year. Financial updates have included revenue shortfalls, a notable revaluation loss on digital assets, and a tight cash position, while the shares have remained well below their 52-week high following an extended drawdown.
Although both target the same underlying asset, their market approaches differ in important ways. HSDT functions as a larger-scale treasury with a roughly four-to-five times bigger SOL balance and a validator business already producing third-party fee revenue, which gives it a more established institutional presence. Its staking yield has stayed above the network average, and the Hong Kong selection adds a clear institutional signal. STKE, on the other hand, is building a more diversified model through Houdini Swap and privacy tools that could expand revenue beyond staking alone. The downside includes a smaller treasury, use of a convertible-note facility to fund further SOL purchases, and greater reliance on leverage, which heightens sensitivity to SOL price drops and contributed to the sharper recent share-price decline. Overall, HSDT provides greater treasury scale and steadier operational progress, while STKE brings more diversification at the cost of higher financial and execution risk.
On the whole, Tickeron's AI currently favors HSDT over STKE. The view rests on measurable factors such as HSDT's larger Solana treasury, its operational validator infrastructure that is already earning third-party fees, consistently stronger staking yields, and recent institutional developments. STKE's diversification efforts appear reasonable, yet its smaller treasury, higher leverage, and softer recent earnings results point to greater volatility and downside exposure. This represents a probabilistic reading of present conditions rather than a prediction, and both stocks remain closely tied to movements in Solana and the wider digital-asset market.
When analyzing names like these, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get a quick sense of momentum shifts across related tickers. The platform also lets me review automated strategies that align with current market conditions, which adds useful context without replacing individual judgment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
HSDT saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 73 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
HSDT moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HSDT crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HSDT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for HSDT entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where HSDT advanced for three days, in 171 of 206 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
HSDT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. HSDT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.688) is normal, around the industry mean (2.423). P/E Ratio (0.010) is within average values for comparable stocks, (8.341). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.318). Dividend Yield (0.000) settles around the average of (0.274) among similar stocks. P/S Ratio (11.574) is also within normal values, averaging (15.906).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HSDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a medical technology company focused on neurological wellness
Industry InvestmentManagers